Monitoring early side effects of methotrexate in brain lymphoma
Part of Cancer clinical trials.
This study observes how your body handles high-dose methotrexate, a chemotherapy drug used to treat your type of lymphoma. The goal is to catch any early side effects and improve how doctors monitor patients on this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with primary central nervous system lymphoma (a type of cancer that starts in the brain or spinal cord).
- You are about to receive high-dose methotrexate (a chemotherapy drug) as your first treatment for this lymphoma.
- You are not currently participating in another clinical research protocol for this lymphoma.
- You are eligible for health coverage under a social security scheme.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a simple spinal fluid test (liquid biopsy) to find and track how primary CNS lymphoma responds to treatment. The goal is to help doctors plan your care with fewer invasive procedures.
This trial tests a combination of orelabrutinib, rituximab, and methotrexate in people with newly diagnosed primary CNS lymphoma (a lymphoma mainly in the brain/spinal fluid). The goal is to see how well the treatment works and how safely it can be given.
This Phase 2 study tests a combination treatment to shrink primary central nervous system lymphoma that starts in the brain, spinal cord, meninges, or eye. It may help patients who have not had anti-cancer treatment yet, but it requires specific cancer type and health conditions.
This trial tests a new combination of drugs (methotrexate, rituximab, sintilimab, and pirtobrutinib) against standard therapy for people with newly diagnosed primary central nervous system lymphoma (PCNSL) that has not been treated before. It aims to see if the combo works better and has manageable side effects.
This Phase 2 trial tests whether giving high-dose methotrexate into the bloodstream can help treat breast cancer that has spread to the thin lining covering the brain and spinal cord. It may help reduce cancer in the leptomeningeal (brain-lining) area and control symptoms.
This Phase 2 study tests whether adding intrathecal methotrexate (a cancer drug delivered into the spinal fluid) to standard chemo can lower the risk of diffuse large B-cell lymphoma (DLBCL) coming back in the brain or spinal fluid. It is for people with higher-than-usual risk of central nervous system (CNS) relapse.
Hear when a new Primary Central Nervous System Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.